Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
3 trials since 2013, 2 ongoing, by the sponsor of the products; see every authorized trial
A phase 2 single-arm, open-label study to assess the safety and efficacy of rituximab plus venetoclax in combination…Jun 6, 2022 · Ongoing · Zandelisib (ME-401) / Rituximab / Venetoclax
A phase 3, randomized, open-label, controlled, multicenter study of zandelisib (ME-401) in combination with rituximab…May 28, 2021 · Closed · Zandelisib (ME-401)
Multicenter, open-label, single-arm, phase 2 study of ME-401 in subjects with follicular lymphoma after failure of two…Dec 24, 2018 · Ongoing · ME-401/ Fludeoxyglucose 18F
Orphan designations (FDA)
One designation since 1983, 0 approved for the designated use, matched by the sponsor's name; see all orphan designations
ZandelisibTreatment of follicular lymphoma · Nov 9, 2021
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.